Lazard Asset Management
HBIO icon

Lazard Asset Management’s Harvard Bioscience HBIO Stock Holding History

Lazard Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-421
Closed -$23K – 2360
2023
Q2 		$23K Buy
+421
New +$23.1K ﹤0.01% 2075
2022
Q4 		– Sell
-712
Closed -$18K – 2459
2022
Q3 		$18K Sell
712
-487
-41% -$16.1K ﹤0.01% 2101
2022
Q2 		$43K Buy
1,199
+487
+68% +$22K ﹤0.01% 1880
2022
Q1 		$44K Buy
712
+497
+231% +$29.4K ﹤0.01% 1807
2021
Q4 		$15K Hold
215
– – ﹤0.01% 2091
2021
Q3 		$15K Hold
215
– – ﹤0.01% 2050
2021
Q2 		$17K Buy
+215
New +$15.2K ﹤0.01% 1867

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Lazard Asset Management's HBIO Position: Q3 2023 in Review

Lazard Asset Management sold out of Harvard Bioscience (HBIO) in Q3 2023, closing a stake of 421 shares — an estimated $23K sold.

Lazard Asset Management first reported a position in HBIO in Q2 2021 and held it in 7 quarters. The position peaked at $44K in Q1 2022. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2023.

  • Lazard Asset Management reported no remaining Harvard Bioscience position as of Q3 2023 after selling out during the quarter.
  • Lazard Asset Management sold 421 Harvard Bioscience shares in Q3 2023, an estimated $23K.
  • Lazard Asset Management first reported a position in Harvard Bioscience in Q2 2021 and held it in 7 quarters.
  • Lazard Asset Management's Harvard Bioscience position peaked at $44K in Q1 2022.
  • 94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2023.

Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.